SCHEMBL4195857

SCHEMBL4195857

N#Cc1cnc2cc(-c3ccncc3)sc2c1-c1cccc(NC(=O)Nc2cccc(Cl)c2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRAF P15056 2/20 0.66
▸ POLB P06746 3/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ LMNA P02545 3/20 0.50
▸ KDM4E B2RXH2 2/20 0.50
▸ GAA P10253 2/20 0.50
▸ HTT P42858 2/20 0.50
▸ HPGD P15428 1/20 0.50
▸ PAX8 Q06710 1/20 0.50
▸ MCL1 Q07820 1/20 0.50
▸ NCOA1 Q15788 1/20 0.50
▸ NCOA3 Q9Y6Q9 1/20 0.50
▸ MEN1 O00255 7/20 0.49
▸ KMT2A Q03164 7/20 0.49
▸ CNR1 P21554 2/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ ALOX15 P16050 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ BLM P54132 4/20 0.44
▸ WRN Q14191 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4204275 0.95 BRAF (0.59) BRAFPOLBSMN1; SMN2LMNAKDM4E
SCHEMBL4203385 0.94 BRAF (0.65) BRAFCNR1BLMWRN
SCHEMBL4196576 0.90 BRAF (0.78) BRAFSMN1; SMN2MEN1KMT2A
SCHEMBL4198711 0.89 BRAF (0.59) BRAFSMN1; SMN2MEN1KMT2ACNR1
SCHEMBL4191033 0.88 BRAF (0.64) BRAFLMNAKDM4EMCL1MEN1
SCHEMBL3976693 0.87 BRAF (0.83) BRAFGAAHTTMEN1KMT2A
SCHEMBL4205760 0.87 BRAF (0.68) BRAFBLMWRNKDR
SCHEMBL4199761 0.86 BRAF (0.69) BRAFCNR1BLMWRNKDR
SCHEMBL4195968 0.85 BRAF (0.70) BRAFPOLBSMN1; SMN2LMNAKDM4E
SCHEMBL4195680 0.84 BRAF (0.74) BRAFPOLBLMNAKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118276-A1 THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS WYETH (US) 2009-05-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118276-A1 THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS BRAF, ARAF, RAF1 BRAF 1/4885POLB 1955/4885SMN1; SMN2 4282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback